Your browser version may not work well with NCBI's Web applications. More information here...
1: PLoS Biol. 2005 Jun;3(6):e176. Epub 2005 May 10.
Related Articles, Links
Click here to read Click here to read Click here to read Click here to read
Inhibition of mutation and combating the evolution of antibiotic resistance.

Cirz RT, Chin JK, Andes DR, de Crécy-Lagard V, Craig WA, Romesberg FE.

Department of Chemistry, The Scripps Research Institute, La Jolla, California, USA.

The emergence of drug-resistant bacteria poses a serious threat to human health. In the case of several antibiotics, including those of the quinolone and rifamycin classes, bacteria rapidly acquire resistance through mutation of chromosomal genes during therapy. In this work, we show that preventing induction of the SOS response by interfering with the activity of the protease LexA renders pathogenic Escherichia coli unable to evolve resistance in vivo to ciprofloxacin or rifampicin, important quinolone and rifamycin antibiotics. We show in vitro that LexA cleavage is induced during RecBC-mediated repair of ciprofloxacin-mediated DNA damage and that this results in the derepression of the SOS-regulated polymerases Pol II, Pol IV and Pol V, which collaborate to induce resistance-conferring mutations. Our findings indicate that the inhibition of mutation could serve as a novel therapeutic strategy to combat the evolution of antibiotic resistance.

Publication Types:
PMID: 15869329 [PubMed - indexed for MEDLINE]

PMCID: PMC1088971